Gastrointestinal Carcinoid Tumors

Carcinoid tumors are a subset of neuroendocrine neoplasms that arise from the enterochromaffin (Kulchitsky) cells of the gastrointestinal (GI) tract. Although they represent only about 12% of all GI malignancies, their incidence has risen in recent decades, largely because of improved imaging and endoscopic techniques. This page provides an overview of the epidemiology, pathology, clinical presentation, diagnosis, staging, treatment, and followup of gastrointestinal carcinoid tumors.

Epidemiology

• Approx. 70% of all carcinoid tumors arise in the GI tract.
• Most common locations: appendix (40%), small intestine (30%), rectum (15%), and stomach (7%).
• Incidence peaks in the fifth to sixth decade of life; slight female predominance overall, but locationspecific differences exist.

Pathology and Classification

Gastrointestinal carcinoids are composed of uniform, round to polygonal cells with stippled saltandpepper chromatin. They may produce a variety of biologically active substances (serotonin, gastrin, etc.), which underlie many of the clinical syndromes.

Current WHO classification (2022) grades tumors based on mitotic count and Ki67 proliferation index:

• Grade1 (NET G1): Ki67 2%, 2 mitoses/2mm.
• Grade2 (NET G2): Ki67 320%, 220 mitoses/2mm.
• Grade3 (NEC): Ki67 >20% or >20 mitoses/2mm; includes poorly differentiated smallcell and largecell types.

Clinical Presentation

Symptoms vary widely depending on tumor size, location, and functional status.

Nonfunctional tumors

• Often discovered incidentally during surgery or imaging for unrelated reasons.
• Can cause obstruction, intussusception (especially in the ileum), or abdominal pain.
• Appendiceal carcinoids are frequently found during appendectomy for presumed appendicitis.

Functional tumors

• Carcinoid syndrome: flushing, diarrhea, wheezing, and rightsided valvular heart disease. Occurs when vasoactive substances bypass hepatic metabolism, usually after metastatic spread to the liver.
• Gastric carcinoids: may produce gastrin leading to refractory peptic ulcer disease (typeI associated with chronic atrophic gastritis, typeII with ZollingerEllison syndrome).
• Appendiceal carcinoids: usually nonfunctional.

Diagnostic Workup

A systematic approach combines biochemical, imaging, and histologic studies.

Biochemical markers

• Chromogranin A (CgA): most sensitive serum marker; elevated in ~70% of GI carcinoids.
• 5Hydroxyindoleacetic acid (5HIAA): measured in 24hour urine; useful for assessing serotoninproducing tumors and monitoring treatment response.
• Other hormone levels (gastrin, insulin, glucagon) when a specific functional syndrome is suspected.

Imaging

• Crosssectional CT or MRI: first line for staging and assessing metastatic disease.
• Somatostatin receptor scintigraphy (Octreoscan) or 68GaDOTATATE PET/CT: highly sensitive for detecting somatostatinreceptor positive lesions; preferred for surgical planning.
• Endoscopic ultrasound (EUS) for rectal and gastric carcinoids enables fineneedle aspiration and depth assessment.

Histopathology

Endoscopic or surgical biopsies are examined with H&E staining and immunohistochemistry for neuroendocrine markers (chromogranin, synaptophysin). Ki67 index and mitotic count determine WHO grade.

Staging

Staging follows the TNM system tailored for neuroendocrine tumors (ENETS/AJCC). Key points:

• T: size, depth of invasion, and mesenteric involvement.
• N: regional lymphnode metastasis.
• M: distant metastasis, most commonly hepatic.

Accurate staging guides therapeutic decisions and prognosis.

Treatment Options

Management is individualized based on tumor grade, size, location, and presence of metastasis.

Surgical Management

• Appendiceal: Simple appendectomy sufficient for tumors 2cm confined to the tip; right hemicolectomy considered for >2cm, mesenteric invasion, or positive margins.
• Smallintestine: Segmental resection with thorough mesenteric lymphnode clearance; often necessary because many are discovered after causing obstruction.
• Rectal: Endoscopic mucosal resection or transanal excision for lesions 1cm; transanal endoscopic microsurgery or low anterior resection for larger lesions.
• Stomach: Endoscopic resection for small (<1cm), welldifferentiated typeI lesions; antrectomy or subtotal gastrectomy for larger or typeII/III tumors.

Medical Therapy

• Somatostatin analogues (octreotide, lanreotide): Firstline for symptom control and tumor growth inhibition; especially effective in functional tumors.
• Targeted therapies: Everolimus (mTOR inhibitor) and sunitinib (tyrosinekinase inhibitor) are approved for advanced pancreatic NETs but can be considered for refractory GI carcinoids.
• Chemotherapy: Limited role; reserved for highgrade (NEC) disease using platinumbased regimens (cisplatin/etoposide).
• Peptide receptor radionuclide therapy (PRRT): 177LuDOTATATE delivers targeted radiation to somatostatinreceptor positive lesions; improves progressionfree survival in metastatic disease.

Interventional Approaches

• Hepatic artery embolization or radiofrequency ablation for liverdominant metastases.
• Transarterial chemoembolization (TACE) as a bridge to surgery or for symptom control.

Prognosis

Overall 5year survival rates differ markedly by stage and grade:

• Localized, lowgrade tumors: >90%.
• Regional lymphnode involvement: 7080%.
• Distant metastasis (primarily hepatic): 3050%.

Highgrade neuroendocrine carcinomas carry a much poorer outlook, with median survival often <12months despite aggressive therapy.

Followup and Surveillance

Longterm monitoring is essential because recurrences can appear years after initial treatment.

• Clinical review every 36months for the first 2years, then annually.
• Serum chromogranin A and, when relevant, 24hour urinary 5HIAA at each visit.
• Imaging: abdominal CT or MRI annually; somatostatinreceptor PET/CT every 23years or sooner if symptoms change.

Living with a Gastrointestinal Carcinoid Tumor

Patients benefit from a multidisciplinary team that includes surgeons, gastroenterologists, medical oncologists, endocrinologists, and nutritionists. Lifestyle considerations include:

• Dietary adjustments to manage diarrhea and flushing (e.g., lowcarbohydrate, lowserotonin foods).
• Avoiding alcohol and niacinrich foods that may precipitate flushing.
• Regular cardiac evaluation because carcinoid heart disease can develop even with wellcontrolled tumor burden.

Key Resources

For further reading and patient support, consult the following:

• National Comprehensive Cancer Network (NCCN) Guidelines Neuroendocrine and Carcinoid Tumors.
• ENETS (European Neuroendocrine Tumor Society) Consensus Guidelines.
• American Cancer Society Carcinoid Tumor Information.
• Carcinoid Cancer Foundation (www.carcinoid.org).

Advances in imaging, molecular pathology, and targeted therapeutics continue to improve outcomes for patients with gastrointestinal carcinoid tumors. Early detection and a personalized treatment plan remain the cornerstones of successful management.